Baricitinib in the Management of Severe Alopecia Areata: A Report of Two Cases with Sustained Clinical Response

Baricitinib, recently approved by the FDA for severe alopecia areata, has shown promise in treating this condition, as well as COVID-19 and rheumatoid arthritis. In a report of two cases, patients with severe alopecia areata (SALT score = 100) were treated with baricitinib, resulting in favorable outcomes and complete hair regrowth over a 12-month follow-up. The treatment is cost-effective, minimally invasive, and requires no postoperative management, though safety and clinical implications should be considered before widespread use.